. Gin4 does not affect Fpk1 localization or level. (A) Wild-type cells (YFR221) or isogenic gin4 cells (YFR224) expressing Fpk1-GFP (top left) from its chromosomal locus, as well as gin4 cells (YAT100) expressing Fpk1-GFP from the TPI1 promoter on a CEN plasmid (pFR150; top right), and wildtype cells (YFR221) expressing Fpk1-GFP from its endogenous promoter and carrying an empty vector [V] (YCpUG) or the same vector overexpressing GIN4 (pMVB115) from the GAL1 promoter (bottom) were grown to mid-exponential phase and viewed with fluorescence microscopy. Bars, 2 µm. (B) The same cells as in A were lysed and the resulting extracts were resolved by SDS-PAGE and analyzed by immunoblotting with anti-GFP and anti-Gin4 antibodies. (C) Sites in the N-terminal regulatory domain of Fpk1 phosphorylated by Gin4 were determined by mass spectrometry, as described in the Materials and methods. Sequence coverage is indicated by bold blue letters. Ser and Thr residues phosphorylated in the presence of Gin4 are indicated in red. Occurrences of the apparent Gin4 consensus sequence (-R/K-x-x-S-) derived from this work and from analysis of synthetic peptide arrays (Mok et al., 2010) , with Arg (purple) and Lys (green) highlighted, are boxed. Asterisks indicate the 10 Ser and 1 Thr mutated to Ala in Fpk1 11A .
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Figure S3. PM flippase activity is required for susceptibility to Myr, but does not affect sphingolipid levels. (A) Wild-type (BY4741, WT) and isogenic dnf1 dnf2 (YFR313) cells were grown at 30°C to mid-exponential phase, then treated with the indicated amount of Myr and cultivated for an additional 8 h. An equivalent number of cells from each culture (2 ml of A 600nm = 1.0) were then labeled with 100 µCi of [ 32 P]H 2 PO 4 for 3 h. Complex (inositol-P-containing) sphingolipids were then extracted and analyzed by ascending TLC and autoradiography as described in the Materials and methods. The identity of the indicated complex sphingolipid species was assigned on the basis of either pharmacological inhibition or mutational ablation of the enzymes responsible for the production of IPC (Aur1), MIPC (Sur1-Csg2 and Csh1-Csg2), and M(IP) 2 C (Ipt1) in control cultures (not depicted). (B) Total sphingoid base (PHS) was generated from equivalent numbers of wild-type (BY4741, WT), isogenic fpk1 fpk2 (YFR205), and Fpk1 11A (YJW2) cells and quantified by HPLC, as described in the Materials and methods. Values represent the mean and SD (error bars) of five independent experiments. n.s., not statistically significant. Figure S4 . KA1 domain-mediated PM targeting of Gin4 is required for its negative regulation of Fpk1 activity. (A) Cells coexpressing Gin4-mCherry and Myo1-GFP (YFR388) were observed by time-lapse microscopy at the indicated times. Bar, 2 µm. (B) Wild-type strain (Y258) expressing Ypk1-myc from the GAL1 promoter (pAM54) and also carrying either an empty vector (BG1805) or the same vector expressing Gin4 (pGin4-zz) or Gin4KA-zz (pFR305) from the GAL1 promoter, were grown to mid-exponential phase, not treated or treated with Myr (1.25 µM), and lysed. The resulting extracts were resolved by SDS-PAGE and analyzed by immunoblotting with anti-c-myc mAb 9E10 and anti-HA antibodies. Figure S5 . Modest elevation of Cdc42 rescues hof1 cells, whereas galactose-driven overexpression is toxic. Cultures of hof1 cells (YFR386) carrying both an empty vector (YCpLG, V), or the same vector expressing CDC42 (PB3050) and pRS316-HOF1, were streaked onto plates containing 5-FOA medium to select against the presence of the URA3-marked pRS316-HOF1 vector. Freshly appearing colonies were then streaked on a second set of 5-FOA plates. The resulting colonies were grown to mid-exponential phase in SCD-L and serial 10-fold dilutions were spotted on SCD-L (Dex, low/leaky expression of GAL prom -CDC42) or SCG-L (Gal, high expression of GAL prom -CDC42) plates. After incubation for 2 d (Dex) or 5 d (Gal) at either 26°C or 37°C, as indicated, the plates were photographed. This null allele is an internal deletion of a 187-bp HindIII-HindIII fragment (nucleotides 305-492) from the HIS3 ORF (Scherer and Davis, 1979) . The FPK 11A allele carries the following substitution mutations of FPK1 (S35A S51A S52A S53A S200A S227A S229A S300A S414A T435A S436A), as described in this study. The mutations carried by this strain represent: his4-580, a strongly polar mutation that drastically reduces all three activities (phosphoribosyl-ATP pyrophosphatase, phosphoribosyl-AMP cyclohydrolase, and histidinol dehydrogenase) encoded in the HIS4 gene product (Fink and Styles, 1974) , but whose molecular identity has not yet been characterized (Fink, G.R., personal communication) ; ura3-52, an insertion of the endogenous yeast retrotransposon Ty1 at codon 121 in the URA3 ORF (and transcribed in the same orientation as would the URA3 mRNA; Rose and Winston, 1984); leu2-3,112 , containing two frameshift mutations that destroy the LEU2 ORF, a G insertion at nucleotide 249, and a G insertion at nucleotide 792, as well as a GTC-to-GTT silent change at codon 56, a GTT-to-GCT missense change at codon 69, a GTT-to-GTC silent change at codon 299, and a GAC-to-AAC missense change at codon 300 (Hinnen et al., 1978); and pep4-3 (Hemmings et al., 1981) , a nonsense mutation converting TGG (Trp) at codon 39 of the PEP4 ORF to TGA (stop; Woolford et al., 1993) . 
